Dr. David Feifel discusses psilocybin’s breakthrough potential for treatment-resistant depression, the psychedelic renaissance, and preparing for a new era in psychiatry.
Editorial Focus
The Evolving Psychedelic Paradigm
Recent Articles on Psychedelics
Original Research
CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial
May 4, 2026
In patients with major depression and suicidal ideation, adding a 16-week CBT course to esketamine led to greater improvements in suicidal ideation and depression severity than esketamine alone.
Consensus Statement
Next-Step Treatment Options for Treatment-Resistant Depression
January 21, 2026
Strong consensus emerged for augmentation with second-generation antipsychotics, TMS, and ketamine/esketamine in the base vignette. Preferences shifted to include non-augmentative antidepressants and ECT based on patient characteristics.
Behind the Manuscript: The Psychedelic Renaissance and Treatment-Resistant Depression with David Feifel, MD, PhD
Listen to the Podcast
Case Series
Esketamine Augmented With Dextromethorphan/Bupropion for Treatment Resistant Depression: A Case Series
November 3, 2025
Three patients with TRD who had no or partial response to esketamine monotherapy as part of a clinical trial received augmentation with dextromethorphan/bupropion 45 mg/105 mg daily.
Original Research
Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
September 3, 2025
Patients treated with ketamine demonstrated superior cognitive functioning compared with those treated with ECT following a 3-week treatment course. No differences between treatments were observed among responders in at…
